BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22654433)

  • 21. Liver metastases from gastric carcinoma: A Case report and review of the literature.
    Polkowska-Pruszyńska B; Rawicz-Pruszyński K; Ciseł B; Sitarz R; Polkowska G; Krupski W; Polkowski WP
    Curr Probl Cancer; 2017; 41(3):222-230. PubMed ID: 28625333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer.
    Saito T; Nakanishi H; Mochizuki Y; Ito S; Ito Y; Misawa K; Yatabe Y; Yamamichi K; Kondo E
    Gastric Cancer; 2015 Oct; 18(4):711-9. PubMed ID: 25173363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival.
    Subasinghe D; Sivaganesh S; Samarsekera A; Kumarasinghe MP; Samarasekera DN; Lokuhetty MDS
    Dig Dis Sci; 2017 Sep; 62(9):2498-2510. PubMed ID: 28612195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.
    Shen GS; Zhao JD; Zhao JH; Ma XF; Du F; Kan J; Ji FX; Ma F; Zheng FC; Wang ZY; Xu BH
    World J Gastroenterol; 2016 Jun; 22(23):5406-14. PubMed ID: 27340357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
    Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
    J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
    BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2 EXPRESSION AS A PROGNOSTIC FACTOR IN METASTATIC GASTRIC CANCER.
    Junior PN; Neto RA; Forones NM
    Arq Gastroenterol; 2016; 53(2):62-7. PubMed ID: 27305410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
    Chen L; Wang L; Li X; Zhang G; Li Z; Wang Y
    DNA Cell Biol; 2021 Feb; 40(2):405-413. PubMed ID: 33605797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma.
    Lv J; Yao YS; Zhou F; Zhuang LK; Yao RY; Liang J; Qiu WS; Yue L
    Med Oncol; 2014 Nov; 31(11):280. PubMed ID: 25297519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.
    Zhang XL; Yang YS; Xu DP; Qu JH; Guo MZ; Gong Y; Huang J
    World J Surg; 2009 Oct; 33(10):2112-8. PubMed ID: 19636613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TFF3 and HER2 expression and their correlation with survival in gastric cancer.
    Gu J; Zheng L; Zhang L; Chen S; Zhu M; Li X; Wang Y
    Tumour Biol; 2015 Apr; 36(4):3001-7. PubMed ID: 25514872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
    Bringolf L; Pestalozzi B; Fink D; Dedes K
    Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
    Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
    Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2.
    Qi M; Jiao M; Li X; Hu J; Wang L; Zou Y; Zhao M; Zhang R; Liu H; Mi J; Zhang L; Liu L; Gong Y; Han B
    Oncogene; 2018 Feb; 37(8):1075-1085. PubMed ID: 29106389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.
    Lei YY; Huang JY; Zhao QR; Jiang N; Xu HM; Wang ZN; Li HQ; Zhang SB; Sun Z
    World J Surg Oncol; 2017 Mar; 15(1):68. PubMed ID: 28327158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 expression and its clinicopathological features in resectable gastric cancer.
    Kataoka Y; Okabe H; Yoshizawa A; Minamiguchi S; Yoshimura K; Haga H; Sakai Y
    Gastric Cancer; 2013 Jan; 16(1):84-93. PubMed ID: 22410801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis.
    Emi Y; Kitamura K; Shikada Y; Kakeji Y; Takahashi I; Tsutsui S
    Surgery; 2002 Jan; 131(1 Suppl):S217-21. PubMed ID: 11821814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.